Patents Assigned to BIOAXONE BIOSCIENCES, INC.
  • Publication number: 20230399311
    Abstract: The present disclosure relates to crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-amine, salts thereof, pharmaceutical compositions thereof, pharmaceutical compositions comprising crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-amine, salts thereof and methods of treatment of neurological conditions including cavernous angioma, cerebral aneurysm, stroke, subarachnoid hemorrhage, vasospasm after subarachnoid hemorrhage, traumatic brain injury, spinal cord injury, spinal cord injury stroke, seizures, hereditary hemorrhagic telangiectasis, cerebral arteriovascular malformations, sporadic cavernous angioma lesion, cerebral cavernous malformation, or combinations thereof, using the same.
    Type: Application
    Filed: June 9, 2023
    Publication date: December 14, 2023
    Applicants: BioAxone BioSciences, Inc., Neurelis, Inc.
    Inventors: Kenneth M. ROSEN, Matthew D. ABBINANTI, Lisa MCKERRACHER, Stuart MADDEN
  • Patent number: 11814361
    Abstract: BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: November 14, 2023
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Kenneth M. Rosen, Matthew D. Abbinanti, Joerg Ruschel, Lisa McKerracher, Lisa Bond Moritz
  • Patent number: 11701366
    Abstract: Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: July 18, 2023
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Kenneth M. Rosen, Steven Wayne Riesinger, Lisa McKerracher, Lisa Bond Moritz
  • Patent number: 11324802
    Abstract: The present invention provides, among other things, improved therapeutic compositions comprising a C3 fusion protein and methods of making and using the same. In particular, the present invention provides improved methods for the treatment of spinal cord injury and other CNS trauma and/or facilitate axon growth or other tissue repair.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: May 10, 2022
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Ricardo Borjas, Mark Fleming, Mei Huang, Mayur Jain, Tapan Sanghvi, Kumkum Saxena, Amaris Torres-Delgado, Ping Yin, Lisa McKerracher, Elizabeth Ryu
  • Publication number: 20220089567
    Abstract: BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.
    Type: Application
    Filed: July 21, 2021
    Publication date: March 24, 2022
    Applicant: BioAxone BioSciences, Inc.
    Inventors: Kenneth M. ROSEN, Matthew D. ABBINANTI, Joerg RUSCHEL, Lisa MCKERRACHER, Lisa BOND MORITZ
  • Patent number: 11198680
    Abstract: BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: December 14, 2021
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Kenneth M. Rosen, Matthew D. Abbinanti, Joerg Ruschel, Lisa McKerracher, Lisa Bond Moritz
  • Patent number: 11098308
    Abstract: Self-delivering PTEN RNA and methods of reducing PTEN expression are provided herein. Also provided are methods of treating spinal cord injury (SCI) and other neurotrauma with PTEN sdRNA.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: August 24, 2021
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Joerg Ruschel, Lisa McKerracher, Emily Niederst, Kenneth M. Rosen
  • Patent number: 10857157
    Abstract: Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: December 8, 2020
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Kenneth M. Rosen, Steven Wayne Riesinger, Lisa McKerracher, Lisa Bond Moritz
  • Patent number: 10537567
    Abstract: Disclosed are therapeutic compositions including BA-1076 and/or BA-2057, methods of their use in the treatment of ophthalmological disorders. The therapeutic compositions may further include an IOP-lowering prostaglandin. The methods may further include administration of an IOP-lowering prostaglandin.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: January 21, 2020
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Joerg Ruschel, Matthew D. Abbinanti, Kenneth M. Rosen, Lisa McKerracher
  • Patent number: 10526313
    Abstract: BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: January 7, 2020
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Kenneth M. Rosen, Matthew D. Abbinanti, Joerg Ruschel, Lisa Mckerracher, Lisa Bond Moritz
  • Patent number: 10149856
    Abstract: Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: December 11, 2018
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Kenneth M. Rosen, Steven Wayne Riesinger, Lisa McKerracher, Lisa Bond Moritz
  • Patent number: 10106525
    Abstract: The disclosure provides rho kinase inhibitor BA-1049(R), an hydroxy metabolite of BA-1049(R), and adipate salts and deuterated forms thereof, useful for treating CNS disorders and injuries.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 23, 2018
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Kenneth M. Rosen, Matthew D. Abbinanti, Joerg Ruschel, Lisa Mckerracher, Lisa Bond Moritz
  • Patent number: 9687483
    Abstract: Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain Rho kinase inhibitors.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: June 27, 2017
    Assignee: BIOAXONE BIOSCIENCES, INC.
    Inventors: Lisa McKerracher, Lisa M. Bond